AR-regulated TWEAK-FN14 pathway promotes prostate cancer bone metastasis

JuanJuan Yin, Yen Nien Liu, Heather Tillman, Ben Barrett, Stephen Hewitt, Kris Ylaya, Lei Fang, Ross Lake, Eva Corey, Colm Morrissey, Robert Vessella, Kathleen Kelly

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The recurrence of prostate cancer metastases to bone after androgen deprivation therapy is a major clinical challenge. We identified FN14 (TNFRSF12A), a TNF receptor family member, as a factor that promotes prostate cancer bone metastasis. In experimental models, depletion of FN14 inhibited bone metastasis, and FN14 could be functionally reconstituted with IKKβ-dependent, NFκB signaling activation. In human prostate cancer, upregulated FN14 expression was observed in more than half of metastatic samples. In addition, FN14 expression was correlated inversely with androgen receptor (AR) signaling output in clinical samples. Consistent with this, AR binding to the FN14 enhancer decreased expression. We show here that FN14 may be a survival factor in low AR output prostate cancer cells. Our results define one upstream mechanism, via FN14 signaling, through which the NFκB pathway contributes to prostate cancer metastasis and suggest FN14 as a candidate therapeutic and imaging target for castrate-resistant prostate cancers.

Original languageEnglish
Pages (from-to)4306-4317
Number of pages12
JournalCancer Research
Volume74
Issue number16
DOIs
Publication statusPublished - Aug 15 2014

Fingerprint

Bone Neoplasms
Androgen Receptors
Prostatic Neoplasms
Neoplasm Metastasis
Bone and Bones
Tumor Necrosis Factor Receptors
Androgens
Theoretical Models
Recurrence
Survival
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Yin, J., Liu, Y. N., Tillman, H., Barrett, B., Hewitt, S., Ylaya, K., ... Kelly, K. (2014). AR-regulated TWEAK-FN14 pathway promotes prostate cancer bone metastasis. Cancer Research, 74(16), 4306-4317. https://doi.org/10.1158/0008-5472.CAN-13-3233

AR-regulated TWEAK-FN14 pathway promotes prostate cancer bone metastasis. / Yin, JuanJuan; Liu, Yen Nien; Tillman, Heather; Barrett, Ben; Hewitt, Stephen; Ylaya, Kris; Fang, Lei; Lake, Ross; Corey, Eva; Morrissey, Colm; Vessella, Robert; Kelly, Kathleen.

In: Cancer Research, Vol. 74, No. 16, 15.08.2014, p. 4306-4317.

Research output: Contribution to journalArticle

Yin, J, Liu, YN, Tillman, H, Barrett, B, Hewitt, S, Ylaya, K, Fang, L, Lake, R, Corey, E, Morrissey, C, Vessella, R & Kelly, K 2014, 'AR-regulated TWEAK-FN14 pathway promotes prostate cancer bone metastasis', Cancer Research, vol. 74, no. 16, pp. 4306-4317. https://doi.org/10.1158/0008-5472.CAN-13-3233
Yin, JuanJuan ; Liu, Yen Nien ; Tillman, Heather ; Barrett, Ben ; Hewitt, Stephen ; Ylaya, Kris ; Fang, Lei ; Lake, Ross ; Corey, Eva ; Morrissey, Colm ; Vessella, Robert ; Kelly, Kathleen. / AR-regulated TWEAK-FN14 pathway promotes prostate cancer bone metastasis. In: Cancer Research. 2014 ; Vol. 74, No. 16. pp. 4306-4317.
@article{6842ed3827c649648cbefae4ce382a15,
title = "AR-regulated TWEAK-FN14 pathway promotes prostate cancer bone metastasis",
abstract = "The recurrence of prostate cancer metastases to bone after androgen deprivation therapy is a major clinical challenge. We identified FN14 (TNFRSF12A), a TNF receptor family member, as a factor that promotes prostate cancer bone metastasis. In experimental models, depletion of FN14 inhibited bone metastasis, and FN14 could be functionally reconstituted with IKKβ-dependent, NFκB signaling activation. In human prostate cancer, upregulated FN14 expression was observed in more than half of metastatic samples. In addition, FN14 expression was correlated inversely with androgen receptor (AR) signaling output in clinical samples. Consistent with this, AR binding to the FN14 enhancer decreased expression. We show here that FN14 may be a survival factor in low AR output prostate cancer cells. Our results define one upstream mechanism, via FN14 signaling, through which the NFκB pathway contributes to prostate cancer metastasis and suggest FN14 as a candidate therapeutic and imaging target for castrate-resistant prostate cancers.",
author = "JuanJuan Yin and Liu, {Yen Nien} and Heather Tillman and Ben Barrett and Stephen Hewitt and Kris Ylaya and Lei Fang and Ross Lake and Eva Corey and Colm Morrissey and Robert Vessella and Kathleen Kelly",
year = "2014",
month = "8",
day = "15",
doi = "10.1158/0008-5472.CAN-13-3233",
language = "English",
volume = "74",
pages = "4306--4317",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "16",

}

TY - JOUR

T1 - AR-regulated TWEAK-FN14 pathway promotes prostate cancer bone metastasis

AU - Yin, JuanJuan

AU - Liu, Yen Nien

AU - Tillman, Heather

AU - Barrett, Ben

AU - Hewitt, Stephen

AU - Ylaya, Kris

AU - Fang, Lei

AU - Lake, Ross

AU - Corey, Eva

AU - Morrissey, Colm

AU - Vessella, Robert

AU - Kelly, Kathleen

PY - 2014/8/15

Y1 - 2014/8/15

N2 - The recurrence of prostate cancer metastases to bone after androgen deprivation therapy is a major clinical challenge. We identified FN14 (TNFRSF12A), a TNF receptor family member, as a factor that promotes prostate cancer bone metastasis. In experimental models, depletion of FN14 inhibited bone metastasis, and FN14 could be functionally reconstituted with IKKβ-dependent, NFκB signaling activation. In human prostate cancer, upregulated FN14 expression was observed in more than half of metastatic samples. In addition, FN14 expression was correlated inversely with androgen receptor (AR) signaling output in clinical samples. Consistent with this, AR binding to the FN14 enhancer decreased expression. We show here that FN14 may be a survival factor in low AR output prostate cancer cells. Our results define one upstream mechanism, via FN14 signaling, through which the NFκB pathway contributes to prostate cancer metastasis and suggest FN14 as a candidate therapeutic and imaging target for castrate-resistant prostate cancers.

AB - The recurrence of prostate cancer metastases to bone after androgen deprivation therapy is a major clinical challenge. We identified FN14 (TNFRSF12A), a TNF receptor family member, as a factor that promotes prostate cancer bone metastasis. In experimental models, depletion of FN14 inhibited bone metastasis, and FN14 could be functionally reconstituted with IKKβ-dependent, NFκB signaling activation. In human prostate cancer, upregulated FN14 expression was observed in more than half of metastatic samples. In addition, FN14 expression was correlated inversely with androgen receptor (AR) signaling output in clinical samples. Consistent with this, AR binding to the FN14 enhancer decreased expression. We show here that FN14 may be a survival factor in low AR output prostate cancer cells. Our results define one upstream mechanism, via FN14 signaling, through which the NFκB pathway contributes to prostate cancer metastasis and suggest FN14 as a candidate therapeutic and imaging target for castrate-resistant prostate cancers.

UR - http://www.scopus.com/inward/record.url?scp=84905963664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905963664&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-13-3233

DO - 10.1158/0008-5472.CAN-13-3233

M3 - Article

C2 - 24970477

AN - SCOPUS:84905963664

VL - 74

SP - 4306

EP - 4317

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 16

ER -